Nelson Dusetti: The Use of Pancreas-View GEM to Personalize Adjuvant Chemotherapy and Improve Outcomes in PDAC
Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared an article on LinkedIn:
“We’re proud to share our latest study validating the Pancreas-View GEM transcriptomic signature for predicting response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma (PDAC).
This work represents an important collaboration between the CRCM – Centre de Recherche en Cancérologie de Marseille and the Dr. Carlos Fernández del Castillo team at Massachusetts General Hospital, and was conducted on an independent patient cohort marking a new step in the broader validation of Pancreas-View predictive signatures.
Our findings support the use of Pancreas-View GEM to personalize adjuvant chemotherapy and improve outcomes in PDAC.”
The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma.
Authors: Louisa Bolm, Nicolas Fraunhoffer, Nelson Dusetti, Julia Straesser, Natalie Petruch, Carlos Fernandez del Castillo, and Juan Iovanna.
You can read the full article on Journal of The Oncologists.
More posts featuring Nelson Dusetti.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023